Recurrent HER2-Positive Breast Carcinoma
1 clinical trials · Condition
◉ Watch Recurrent HER2-Positive Breast Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer (NCT03199885) | National Cancer Institute (NCI) | 2019-04-05 |
Track Recurrent HER2-Positive Breast Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.